Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the ...

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

Amsterdam, The Netherlands Monday, June 23, 2025, 12:00 Hrs [IST] ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

Revolutionary advancements in blood cancer treatment, from targeted therapy to gene editing, promise more effective and ...

John J. York's portrayal of Malcolm "Mac" Scorpio has been a beloved and enduring General Hospital character for decades.

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.